MedCity News
SEPTEMBER 8, 2024
As poverty, food insecurity, inadequate housing, and complex comorbidities persist, it is essential that rural healthcare leaders have tools and systems in place to address the health of their neighbors. The post Rural Healthcare Goes Beyond Care: Targeting SDOH to Improve Health Outcomes appeared first on MedCity News.
Fierce Pharma
SEPTEMBER 8, 2024
The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. | The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
SEPTEMBER 8, 2024
As the FDA continues its work to ensure that AI is deployed safely within healthcare, there are a couple prevalent issues that frequently pop up, said Luke Ralston, one of the agency’s reviewers. The post These Are 2 of The Biggest Issues with Healthcare AI, According to an FDA Reviewer appeared first on MedCity News.
pharmaphorum
SEPTEMBER 8, 2024
CDC reports the first-ever US case of an H5 strain of avian influenza without a known occupational exposure to sick or infected animals
Advertiser: ZoomInfo
AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.
MedCity News
SEPTEMBER 8, 2024
NeOnc Technologies is preparing to go public via the less common path of a direct listing as it continues mid-stage testing of its intranasally administered brain cancer drug. Meanwhile, the mostly stagnant biotech IPO pipeline is showing new signs of life with two large stock market debuts expected this week. The post A Biotech Going Through the Nose to Treat the Brain Plots Alternative Path to Public Markets appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
SEPTEMBER 8, 2024
The ruling, which limits federal agencies’ power to interpret ambiguous laws, now leaves crucial legislation like the Mental Health Parity and Addiction Equity Act vulnerable to court challenges, potentially unraveling years of hard-won progress. The post Supreme Court’s Chevron Decision Threatens Decades of Progress in Access to Mental Health Care appeared first on MedCity News.
Pharmaceutical Technology
SEPTEMBER 8, 2024
Botanical Solution Inc.
Clarivate
SEPTEMBER 8, 2024
A new Clarivate report [1] explores Standard Essential Patents Landscape of 5G RedCap The RedCap (Reduced Capability) feature was introduced by 3GPP in Release-17 to cater to the growing demand for 5G New Radio (NR) devices with reduced complexity. 5G RedCap, also known as NR-Light, addresses the need for simpler, energy efficient and cost effective 5G NR devices.
PharmaTech
SEPTEMBER 8, 2024
Drug stability impacts efficacy and safety. Choosing the right packaging is crucial. This paper outlines key factors affecting stability and provides packaging guidelines.
Speaker: Jesse Hunter and Brynn Chadwick
Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.
Pharmaceutical Technology
SEPTEMBER 8, 2024
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Mantle Cell Lymphoma.
PharmaTech
SEPTEMBER 8, 2024
Insights into molecular behaviors and predictive capabilities are bringing numerous benefits.
Pharmaceutical Technology
SEPTEMBER 8, 2024
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Relapsed Acute Myeloid Leukemia.
Pharmaceutical Technology
SEPTEMBER 8, 2024
PEP-07 is under clinical development by Sentinel Oncology and currently in Phase I for Refractory Acute Myeloid Leukemia.
Advertiser: ZoomInfo
ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!
Pharmaceutical Technology
SEPTEMBER 8, 2024
MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Pearson Syndrome.
Pharmaceutical Technology
SEPTEMBER 8, 2024
MNV-201 is under clinical development by Minovia Therapeutics and currently in Phase I for Subacute Necrotizing Encephalomyelopathy (Leigh Disease).
Pharmaceutical Technology
SEPTEMBER 8, 2024
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers.
Pharmaceutical Technology
SEPTEMBER 8, 2024
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease.
Speaker: Kevin Burke
AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.
Pharmaceutical Technology
SEPTEMBER 8, 2024
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer.
Pharmaceutical Technology
SEPTEMBER 8, 2024
Sonidegib phosphate is under clinical development by Sun Pharma Advanced Research and currently in Phase I for Non-Small Cell Lung Cancer.
Pharmaceutical Technology
SEPTEMBER 8, 2024
Safinamide mesylate is under clinical development by Zambon Co and currently in Phase II for Drug-Induced Dyskinesia.
Pharmaceutical Technology
SEPTEMBER 8, 2024
SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Ovarian Cancer.
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
Pharmaceutical Technology
SEPTEMBER 8, 2024
SON-DP is under clinical development by Qurgen and currently in Phase I for Metastatic Colorectal Cancer.
Pharmaceutical Technology
SEPTEMBER 8, 2024
Interferon alfa-2b is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase II for Genital Warts (Condylomata Acuminata).
Pharmaceutical Technology
SEPTEMBER 8, 2024
RD-129 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Autoimmune Disorders.
Pharmaceutical Technology
SEPTEMBER 8, 2024
MAR-001 is under clinical development by Marea Therapeutics and currently in Phase II for Hypertriglyceridemia.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Pharmaceutical Technology
SEPTEMBER 8, 2024
JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Autoimmune Disorders.
Pharmaceutical Technology
SEPTEMBER 8, 2024
JTE-162 is under clinical development by Japan Tobacco and currently in Phase I for Inflammation.
Pharmaceutical Technology
SEPTEMBER 8, 2024
Omalizumab biosimilar is under clinical development by Kashiv BioSciences and currently in Phase III for Chronic Urticaria Or Hives.
Expert insights. Personalized for you.
335 
Let's personalize your content